Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

Proteins that play key roles in the development of diseases such as cancer and inflammation may...

Molecules produced by gut bacteria upon digestion of dietary fibre can improve the function of...

The coronary sinus reducer is understood to redistribute blood flow within the wall of the heart,...

Content from other channels on our network

Sparc Hydrogen pilot plant achieves sustained generation

ACSC issues guidance on using AI in critical infrastructure

Bestech acquires Measurement Solutions Australia

foodpro to return to Melbourne in 2026

Australia must rethink the foundations of industrial automation

Improving shelf life of blueberries with upcycled edible coating

Food manufacturers lead the way in Manufacturing Health Index report

Apricot packaging goes linerless

Aussie Barramundi farm achieves certification for responsible aquaculture

Five trends reshaping the snack food industry

First nature-related financial disclosure for university

Calls for efficiency standards for data centre water use

Vodafone and MobileMuster team up to tackle e-waste

$39m boost to NSW's EV fast charging network

Australia on way to meet EEC targets